The meaning of SEND and its importance

SEND (Standard for Exchange of Nonclinical Data, non-clinical data exchange standard) is defined and maintained by the SEND team of the Clinical Data Inter-change Standards Consortium (CDISC). SEND is a method for collecting and presenting nonclinical data and is one of the required standards for submitting data to the FDA.

SEND Importance

According to the requirements of the US FDA, after December 17, 2016, applications for general toxicity tests (including single and multiple dose general toxicity tests) and carcinogenicity tests for NDA, ANDA, and BLA must be submitted in accordance with the SEND format standard; 2017 After December 17, 2019, general toxicity tests (including single and multiple dose general toxicity tests) for IND applications must also use the SEND format.

Safety pharmacology trials for NDA and BLA applications conducted after March 15, 2019, and safety pharmacology trials for IND applications conducted after March 15, 2020, are also required to be submitted to the FDA in SEND format. SENDIG 3.1 contains a subset of safety pharmacology, including respiratory and cardiovascular studies.

CDISC released the SEND standard SENDIG-AR for animal regulatory studies on September 17, 2019. FDA began to support this standard after March 15, 2020. For studies initiated after March 15, 2022, animal regulatory research The SEND dataset is required when submitting to the Center for Drug Evaluation and Research (CDER), depending on the type of regulatory submission.

On March 15, 2021, SENDIG-DART v1.1 was included in the FDA catalog and is based on SEND v 3.1 for the assessment of reproductive toxicity of antineoplastic drugs (primarily embryonic development (EFD)). Antineoplastic drug reproductive toxicity studies are required to use the SEND dataset for studies expected to initiate after March 15, 2023.

[1].SEND | CDISC https://www.cdisc.org/standards/foundational/send

[2].https://www.fda.gov/drugs/news-events-human-drugs/send-cber-what-you-need-know-12042020

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客